Ansell Healthcare Europe NV/SA
—
Riverside Business Park – Block J
Boulevard International 55
1070 Brussels, Belgium

T. + 32 (0)2 528 74 00
F. + 32 (0)2 528 74 01
Email: info.europe@ansell.com
www.ansell.com

EU DECLARATION OF CONFORMITY

Manufacturer Name/Address: Ansell Healthcare Europe NV/SA
Riverside Business Park,
Block J, Boulevard International 55,
1070 Brussels,
Belgium

SRN Number: BE-MF-000000691

Risk Class: Class I

Intended Purpose: A non-sterile medical device intended as an examination/treatment glove and a protective barrier when worn on the hands of healthcare providers, during patient examination, or for other sanitary purposes. The device is used mainly as a two-way barrier to protect both the patient and wearer against contaminants. This is a single-use device.

EMDN Code and Description: T01020204 - Nitrile Examination/Treatment Glove

Basic UDI-DI: 5414566 MF93862 F2

Product Name(s):

Product Name	Size	Product Code	Market Regions
Microflex® 93-862 MidKnight™ Xtra	S (6.5-7.0)	93862070	NA/EMEA
Microflex® 93-862 MidKnight™ Xtra	M (7.5-8.0)	93862080	NA/EMEA
Microflex® 93-862 MidKnight™ Xtra	L (8.5-9.0)	93862090	NA/EMEA
Microflex® 93-862 MidKnight™ Xtra	XL (9.5-10.0)	93862100	NA/EMEA
Microflex® 93-862 MidKnight™ Xtra	XXL (10.5-11)	93862110	NA/EMEA
Microflex® 93-862 MidKnight™ Xtra	Sample Pack	93862000-SAMP	NA/EMEA

Conformity Assessment Procedure: Annex I & Annex II + Annex III

This EU Declaration of Conformity is issued under the sole responsibility of Ansell Healthcare Europe NV/SA.

Ansell Healthcare Europe NV/SA
—
Riverside Business Park – Block J
Boulevard International 55
1070 Brussels, Belgium

T. + 32 (0)2 528 74 00
F. + 32 (0)2 528 74 01
Email: info.europe@ansell.com
www.ansell.com

We hereby declare that the medical device(s) specified above meet the provision of the Regulation (EU) MDR 2017/745 for medical devices.

Signed on behalf of Ansell Healthcare Europe NV

Ansell Healthcare Europe NV
Riverside Business Park - Block J
Bld Internationalelaan 55
B-1070 Brussels
BELGIUM

Name: Samantha Marshall
Position: Director Regulatory Affairs Medical EMEA / APAC
Date of issue: 02 March 2023
Place of issue: Nuneaton, England
Version No: MED\MFXMKNIGHTXTR\003